
|Articles|January 15, 2007
Clinical trial under way for topical AMD therapy
San Diego-TargeGen has begun a phase I trial of a topical drug to treat age-related macular degeneration (AMD).
Advertisement
San Diego-TargeGen has begun a phase I trial of a topical drug to treat age-related macular degeneration (AMD).
The single-site, 45-patient study will test its small-molecule, multitargeted kinase inhibitor TG100801 as a therapy for AMD and other eye diseases.
The eye drop suppresses disease-related edema, angiogenesis, and inflammation. TargeGen expects to complete the phase I study by the end of the first quarter of 2007, with plans to start a phase II trial by mid-year.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
3
The Residency Report: Cardiovascular risk scores as a window into ocular disease
4
Study links alcohol consumption to earlier advanced presbyopia in men
5





















